Skip to main content

stock

ARCT · Arcturus Therapeutics Holdings Inc.

What Arcturus Therapeutics Holdings Inc. reports to the SEC, read from its filings.

Open in the app

Price

The live ARCT price and today's change.

Sign in to see this

Chart

Thirty days of daily bars, with signal levels drawn on them.

Sign in to see this

Signals

The latest signal group Nakagai's scanner recorded on ARCT.

Sign in to see this

Options positioning

Gamma exposure levels from the options market.

Sign in to see this

Technicals

Trend, momentum and volatility gauges per timeframe.

Sign in to see this

What it is

Industry
Pharmaceutical Preparations (SIC 2834)
Filer (SEC EDGAR)
EDGAR filing index
Shares outstanding
28,423,069 as of 2026-08-04 (XBRL frame CY2026Q2I)

Key stats

Valuation

P/E
Locked
P/S
Locked
P/B
Locked
Enterprise value
Locked
EV/EBIT
Locked
FCF yield
Locked

Margins

Gross
—
Operating
-348.3%
Net
-317.6%

Returns

ROE
-54.3%
ROA
-41.6%

Health

Current ratio
5.9x
Debt/equity
—

Deep value

NCAV
$144.66M
NCAV per share
$5.09
Price/NCAV
Locked
NNWC
$140.34M
NNWC per share
$4.94
Price/NNWC
Locked

Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.

Sign in to see this

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenueGross profit (not reported by this company)Operating incomeNet incomeFiling
2026-06-30$2.96M—Gross profit: unreported by this company.-$25.55M-$23.79M
10-Q filed 2026-08-06
2026-03-31$2.06M—Gross profit: unreported by this company.-$28.93M-$26.96M
10-Q filed 2026-08-06
Assembled from more than one filing; the filing above is only the newest of them.
2025-12-31$7.20M—Gross profit: unreported by this company.-$31.31M-$29.08M
10-K filed 2026-03-03
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
2025-09-30$17.15M—Gross profit: unreported by this company.-$16.51M-$13.45M
10-Q filed 2025-11-12
2025-06-30$28.30M—Gross profit: unreported by this company.-$11.62M-$9.18M
10-Q filed 2026-08-06
2025-03-31$29.38M—Gross profit: unreported by this company.-$16.83M-$14.08M
10-Q filed 2026-08-06
Assembled from more than one filing; the filing above is only the newest of them.
2024-12-31$22.77M—Gross profit: unreported by this company.-$33.39M-$30.00M
10-K filed 2026-03-03
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
2024-09-30$41.67M—Gross profit: unreported by this company.-$10.74M-$6.90M
10-Q filed 2025-11-12
Assets
$224.31M
Equity
$171.81M

Balance as of 2026-06-30.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
2025-12-31$82.03M-$76.26M-$65.78M-$74.50M
2024-12-31$152.31M-$95.67M-$80.94M-$60.40M
2023-12-31$166.80M-$78.20M-$29.73M-$21.00M
2022-12-31$206.00M$12.18M$9.35M$24.27M
2021-12-31$12.36M-$202.85M-$203.67M-$138.45M
2020-12-31$9.54M-$71.52M-$72.15M-$44.60M
2019-12-31$20.79M-$25.51M-$25.99M-$7.26M
2018-12-31$15.75M-$21.81M-$21.79M-$22.24M

Company filings

since Tue Dec 30

events

  • Regulation FD disclosure

    Regulation FD disclosure
    Sep 238-K
  • Regulation FD disclosure

    Regulation FD disclosure
    Aug 258-K
  • Results

    Results
    Aug 68-K
  • Material agreement, Regulation FD disclosure

    Material agreementRegulation FD disclosure
    Jul 28-K
  • Shareholder vote results

    Shareholder vote results
    Jun 58-K
  • Results, Executive or director change, Regulation FD disclosure

    ResultsExecutive or director changeRegulation FD disclosure
    May 78-K

5% owners ()

Insiders, politicians and funds

Insider trades, last 90 days

Politician trades, last 90 days

Funds

News

Stories that named ARCT, and the market events around them.

Sign in to see this

Board

The ARCT board could not be loaded.

Retry the ARCT board

nakagai

Signals on ARCT come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Members post on the ARCT board

This page is not financial advice. Trade at your own judgment and risk. Read the terms that govern posting here.

Arcturus Therapeutics Holdings Inc. (ARCT): SEC filings, financials and insider trades · Nakagai